Fibrocell Science Inc (NASDAQ:FCSC)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued on Thursday. They presently have a $7.60 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 151.66% from the company’s previous close.

Several other research analysts have also recently weighed in on FCSC. ValuEngine upgraded Fibrocell Science from a “strong sell” rating to a “sell” rating in a report on Thursday, June 15th. Zacks Investment Research upgraded Fibrocell Science from a “hold” rating to a “buy” rating and set a $4.25 target price on the stock in a report on Wednesday, July 12th. Finally, Canaccord Genuity restated a “buy” rating and set a $7.00 target price (up from $3.00) on shares of Fibrocell Science in a report on Monday, September 11th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. Fibrocell Science presently has a consensus rating of “Hold” and a consensus target price of $5.21.

Shares of Fibrocell Science (NASDAQ FCSC) opened at 3.02 on Thursday. Fibrocell Science has a 12 month low of $1.57 and a 12 month high of $4.64. The firm’s 50-day moving average price is $2.99 and its 200-day moving average price is $2.79. The stock’s market capitalization is $44.45 million.

Fibrocell Science (NASDAQ:FCSC) last issued its earnings results on Wednesday, August 9th. The company reported ($0.31) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.31). On average, equities research analysts forecast that Fibrocell Science will post ($2.17) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Fibrocell Science Inc (FCSC) Receives Buy Rating from HC Wainwright” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://www.americanbankingnews.com/2017/10/05/fibrocell-science-inc-fcsc-receives-buy-rating-from-hc-wainwright.html.

An institutional investor recently raised its position in Fibrocell Science stock. Creative Planning increased its position in shares of Fibrocell Science Inc (NASDAQ:FCSC) by 395.3% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 61,090 shares of the company’s stock after buying an additional 48,755 shares during the quarter. Creative Planning owned about 0.42% of Fibrocell Science worth $245,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 54.70% of the company’s stock.

Fibrocell Science Company Profile

Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

Receive News & Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related companies with MarketBeat.com's FREE daily email newsletter.